Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.50 |
| ▸ | PI4KA | P42356 | 5/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.50 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189832 | 1.00 | PIK3CD (0.50) | PIK3CDPIK3CAPIK3CBPI4KAPI4KB | |
| SCHEMBL23720038 | 0.81 | CYP3A4 (0.43) | PIK3CDPIK3CAPIK3CBPI4KAPI4KB | |
| SCHEMBL30526543 | 0.81 | PIK3CD (0.55) | PIK3CDPIK3CAPIK3CBPI4KAPI4KB | |
| SCHEMBL184788 | 0.81 | PIK3CD (0.53) | PIK3CDPIK3CAPIK3CBPI4KAPI4KB | |
| SCHEMBL184566 | 0.81 | PIK3CD (0.55) | PIK3CDPIK3CAPIK3CBPI4KAPI4KB | |
| SCHEMBL30526584 | 0.80 | PIK3CA (0.57) | PIK3CDPIK3CAPIK3CBPI4KAPI4KB | |
| SCHEMBL30189846 | 0.79 | PDE10A (0.36) | PIK3CDPIK3CAPIK3CBPI4KAPI4KB | |
| SCHEMBL794336 | 0.79 | PDE10A (0.36) | PIK3CDPIK3CAPIK3CBPI4KAPI4KB | |
| SCHEMBL10049899 | 0.79 | PDE10A (0.44) | PIK3CDPIK3CAPIK3CBPI4KAPI4KB | |
| SCHEMBL1851332 | 0.78 | PDE10A (0.35) | PIK3CDPIK3CAPIK3CBPI4KAPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | claimed |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | BEIGENE, LTD. (KY) | 2025-01-23 | — | — | US | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2023234970-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA Therapeutics, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-11447482-B1 | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis | KUDA Therapeutics, Inc. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | KUDA Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | KUDA Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| WO-2021110890-A1 | PYRIDINIUM DERIVATIVES AS HERBICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2021-06-10 | — | — | WO | disclosed |
| EP-1680431-A1 | BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050282851-A1 | Substituted (thiazol-2-yl)-amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes | NOVARTIS AG (CH) | 2005-12-22 | — | — | US | disclosed |
| WO-2005095418-A1 | SULFONAMIDE-THIAZOLPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS USEFUL THE TREATMENT OF TYPE 2 DIABETES | NOVARTIS AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095417-A1 | THIAZOLOPYRIDINE DERIVATES, PHARMACEUTICAL CONDITIONS CONTAINING THEM AND METHODS OF TREATING GLUCOKINASE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| EP-1549626-A1 | SUBSTITUTED (THIAZOL-2-YL) -AMIDE OR SULFONAMIDE AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES | Novartis AG (CH) | 2005-07-06 | — | — | EP | disclosed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2004050645-A1 | SUBSTITUTED (THIAZOL-2-YL) -AMIDE OR SULFONAMIDE AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES | NOVARTIS AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| EP-0973775-A1 | PYROLOPYRROLONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998043975-A1 | PYROLOPYRROLONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | UBQLN1, UBE2T, NEDD4 | PIK3CD 630/4885PIK3CA 893/4885PIK3CB 409/4885 |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | PIK3CD 1738/4885PIK3CA 524/4885PIK3CB 1711/4885 |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | HIF1AN, HIF1A, EGLN2 | PIK3CD 861/4885PIK3CA 1071/4885PIK3CB 1357/4885 |
| US-11447482-B1 | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis | HIF1AN, HIF1A, EGLN2 | PIK3CD 601/4885PIK3CA 767/4885PIK3CB 927/4885 |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | HIF1AN, HIF1A, EGLN2 | PIK3CD 601/4885PIK3CA 767/4885PIK3CB 927/4885 |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | PIK3CD 3208/4885PIK3CA 3307/4885PIK3CB 3975/4885 |
| US-20050282851-A1 | Substituted (thiazol-2-yl)-amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes | GCKR, GCK, GPR119 | PIK3CD 2887/4885PIK3CA 2351/4885PIK3CB 2218/4885 |
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | POLQ, POLK, POLI | PIK3CD 454/4885PIK3CA 386/4885PIK3CB 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.